Karyopharm Therapeutics Inc. Stock
Karyopharm Therapeutics Inc. is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
With a target price of 17 € there is potential for a 3041.17% increase which would mean more than doubling the current price of 0.54 € for Karyopharm Therapeutics Inc..
Our community identified positive and negative aspects for Karyopharm Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Karyopharm Therapeutics Inc. stock. On the other hand our users think that "Unique positioning" could be a problem in the future.
Pros and Cons of Karyopharm Therapeutics Inc. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Karyopharm Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | 0.550% | 9.116% | -16.979% | -59.489% | -12.433% | -55.252% | -93.116% |
| Evolus Inc | -1.250% | 6.878% | 4.124% | -69.624% | -25.872% | -52.471% | -63.604% |
| Sangamo Therapeutics Inc. | 3.720% | -15.248% | 10.729% | -58.174% | -3.230% | -87.303% | -96.400% |
Comments
Karyopharm Therapeutics (NASDAQ:KPTI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) had its price target lowered by analysts at Royal Bank Of Canada from $30.00 to $19.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for KPTI provided by MarketBeat